Skip to main content

Advertisement

SpringerLink
Log in

The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis

  • Genes and Disease
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Oxidative stress is believed to be of great importance for both the etiology and the persistence of juvenile idiopathic arthritis (JIA). The aim of this study was to investigate the association of -262C/T polymorphism of the catalase (CAT) gene with JIA, as well as to evaluate whether this polymorphism can influence plasma CAT activity and outcome in JIA patients treated with etanercept. A total of 154 subjects (60 JIA patients and 94 healthy volunteers) were screened for CAT-262C/T gene polymorphism using the polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) method. Plasma CAT activity was determined using the spectrophotometric method according to Goth, prior to and 12 months after anti-TNF (etanercept) therapy. Clinical outcome was assessed using the JIA ACR (American College of Rheumatology) response criteria. The genotype and allele frequency distributions of CAT-262C/T polymorphism in the patients were significantly different from those of the controls (p = 0.014, p = 0.006). The TT genotype (polymorphic homozygous) was associated with a 4.36-fold higher likelihood of having JIA (95% CI 1.545–12.323, p = 0.005) as compared to the CC genotype (wild-type). At month 12 of treatment, JIA patients, carriers of the CC genotype, showed significantly higher plasma CAT activity (p = 0.004) and achieved the JIA ACR 70 response more often (p = 0.003) than the patients, carriers of the CT/TT genotype. This is the first study implying the possible association of CAT-262C/T polymorphism with JIA. The results suggest the potential protective effect of the CC genotype, with regard to CAT activity and treatment outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392

    Google Scholar 

  2. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344(12):907–916. https://doi.org/10.1056/NEJM200103223441207

    Article  CAS  Google Scholar 

  3. Pavlović D, Đorđević V, Kocić G (2002) Signal transduction—free radical modulation. Jugoslov Med Biohem 21(2):69–84. https://doi.org/10.2298/JMH0202069P

    Article  Google Scholar 

  4. Umar S, Kumar A, Sajad M, Zargan J, Ansari M, Ahmad S et al (2013) Hesperidin inhibits collagen-induced arthritis possibly through suppression of free radical load and reduction in neutrophil activation and infiltration. Rheumatol Int 33(3):657–663. https://doi.org/10.1007/s00296-012-2430-4

    Article  CAS  PubMed  Google Scholar 

  5. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A (2008) Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 28(3):245–251. https://doi.org/10.1007/s00296-007-0419-1

    Article  CAS  PubMed  Google Scholar 

  6. Kodydková J, Vávrová L, Kocík M, Žák A (2014) Human catalase, its polymorphisms, regulation and changes of its activity in different diseases. Folia Biol (Praha) 60(4):153–167

    Google Scholar 

  7. Ramos VA, Ramos PA, Dominguez MC (2000) Role of oxidative stress in the maintenance of inflammation in patients with juvenile rheumatoid arthritis. J Pediatr 76(2):125–132

    Article  CAS  Google Scholar 

  8. Ashour M, Salem S, Hassaneen H, El-Gadban H, Elwan N, Awad A, Basu TK (2000) Antioxidant status in children with juvenile rheumatoid arthritis (JRA) living in Cairo, Egypt. Int J Food Sci Nutr 51(2):85–90

    Article  CAS  PubMed  Google Scholar 

  9. Sklodowska M, Gromadzinska J, Biernacka M, Wasowicz W, Wolkanin P, Marszalek A et al (1996) Vitamin E, thiobarbituric acid reactive substance concentrations and superoxide dismutase activity in the blood of children with juvenile rheumatoid arthritis. Clin Exp Rheumatol 14(4):433–439

    CAS  PubMed  Google Scholar 

  10. Ensembl base (2018) Transcript: CAT-201. http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000121691;r=11:34438925-34472062;t=ENST00000241052. Accessed 22 Oct 2018

  11. Chistiakov A, Zotova EV, Savosťanov KV, Bursa TR, Galeev IV, Strokov IA, Nosikov VV (2006) The 262T> C promoter polymorphism of the catalase gene is associated with diabetic neuropathy in type 1 diabetic Russian patients. Diabetes Metab 32(1):63–68

    Article  CAS  PubMed  Google Scholar 

  12. Shen Y, Li D, Tian P, Shen K, Zhu J, Feng M et al (2015) The catalase C-262T gene polymorphism and cancer risk: a systematic review and meta-analysis. Medicine (Baltimore) 94(13):e679–e686. https://doi.org/10.1097/MD.0000000000000679

    Article  CAS  Google Scholar 

  13. Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD et al (2008) Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 17(5):1082–1087. https://doi.org/10.1158/1055-9965.EPI-07-2755

    Article  CAS  PubMed  Google Scholar 

  14. Ezzikouri S, El Feydi AE, Afifi R, Benazzouz M, Hassar M, Pineau P, Benjelloun S (2010) Polymorphisms in antioxidant defence genes and susceptibility to hepatocellular carcinoma in a Moroccan population. Free Radic Res 44(2):208–216. https://doi.org/10.3109/10715760903402906

    Article  CAS  PubMed  Google Scholar 

  15. Khodayari S, Salehi Z, Fakhrieh Asl S, Aminian K, Mirzaei Gisomi N, Torabi Dalivandan S (2013) Catalase gene C-262T polymorphism: importance in ulcerative colitis. J Gastroenterol Hepatol 28(5):819–822. https://doi.org/10.1111/jgh.12141

    Article  CAS  PubMed  Google Scholar 

  16. Hebert-Schuster M, Fabre EE, Nivet-Antoine V (2012) Catalase polymorphisms and metabolic diseases. Curr Opin Clin Nutr Metab Care 15(4):397–402. https://doi.org/10.1097/MCO.0b013e328354a32

    Article  CAS  PubMed  Google Scholar 

  17. Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I et al (2017) Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 19(1):256. https://doi.org/10.1186/s13075-017-1462-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40(7):1202–1209

    Article  CAS  PubMed  Google Scholar 

  19. Forsberg L, Lyrenas L, de Faire U, Morgenstern R (2001) A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 30(5):500–505

    Article  CAS  PubMed  Google Scholar 

  20. Goth L (1991) A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 196(2–3):143–152

    Article  CAS  PubMed  Google Scholar 

  21. Goţia S, Popovici I, Hermeziu B (2001) Antioxidant enzymes levels in children with juvenile rheumatoid arthritis. Rev Med Chir Soc Med Nat Iasi 105(3):499–503

    PubMed  Google Scholar 

  22. Winsz-Szczotka K, Kuźnik-Trocha K, Komosińska-Vassev K, Jura-PóBtorak A, Olczyk K (2016) Laboratory indicators of aggrecan turnover in juvenile idiopathic arthritis. Dis Markers 2016:7157169. https://doi.org/10.1155/2016/7157169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Araujo V, Arnal C, Boronat M, Ruiz E, Dominguez C (1998) Oxidant–antioxidant imbalance in blood of children with juvenile rheumatoid arthritis. Biofactors 8(1–2):155–159

    Article  CAS  PubMed  Google Scholar 

  24. Winsz-Szczotka K, Komosińska-Vassev K, Kuźnik-Trocha K, Gruenpeter A, Lachór-Motyka I, Olczyk K (2014) Influence of proteolytic–antiproteolytic enzymes and prooxidative–antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis. Clin Biochem 47(9):829–834. https://doi.org/10.1016/j.clinbiochem.2014.01.027

    Article  CAS  PubMed  Google Scholar 

  25. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093–1101. https://doi.org/10.1002/art.10885

    Article  CAS  PubMed  Google Scholar 

  26. Halbig M, Horneff G (2009) Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 30(2):229–238. https://doi.org/10.1007/s00296-009-0942-3

    Article  CAS  PubMed  Google Scholar 

  27. Min JY, Lim SO, Jung G (2010)) Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter. FEBS Lett 584(11):2427–2432. https://doi.org/10.1016/j.febslet.2010.04.048

    Article  CAS  PubMed  Google Scholar 

  28. Alexeeva EI, Namazova-Baranova LS, Bzarova TM, Valieva SI, Denisova RV, Sleptsova TV et al (2017) Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J 15(1):51. https://doi.org/10.1186/s12969-017-0178-9

    Article  PubMed  PubMed Central  Google Scholar 

  29. Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Gulli R et al (2018) Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Mod Rheumatol 28(3):417–431. https://doi.org/10.1080/14397595.2017.1366006

    Article  CAS  PubMed  Google Scholar 

  30. De Sanctis S, Marcovecchio ML, Gaspari S, Del Torto M, Mohn A, Chiarelli F et al (2013) Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J Rheumatol 40(6):943–948. https://doi.org/10.3899/jrheum.121281

    Article  CAS  PubMed  Google Scholar 

  31. Hunter H (2018) Question 2: Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis? Arch Dis Child 103(11):1087–1089. https://doi.org/10.1136/archdischild-2018-315528

    Article  PubMed  Google Scholar 

  32. Alexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, Fetisova A, Mamutova A, Alshevskaya A, Gladkikh V, Moskalev A (2018) Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method. Mod Rheumatol. https://doi.org/10.1080/14397595.2018.1516329

    Article  PubMed  Google Scholar 

  33. Basic J, Pavlovic D, Jevtovic-Stoimenov T, Vojinovic J, Susic G, Stojanovic I et al (2010) Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype. J Physiol Biochem 66(2):173–180. https://doi.org/10.1007/s13105-010-0022-x

    Article  CAS  PubMed  Google Scholar 

  34. Bašić J, Vojinović J, Jevtović-Stoimenov T, Despotović M, Sušić G, Lazarević D et al (2018) Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis. Clin Rheumatol. https://doi.org/10.1007/s10067-018-4264-2

    Article  PubMed  Google Scholar 

  35. Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I et al (2016) Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol 43(4):816–824. https://doi.org/10.3899/jrheum.150430

    Article  CAS  PubMed  Google Scholar 

  36. Saify K, Saadat I, Saadat M (2016) Influence of A-21T and C-262T genetic polymorphisms at the promoter region of the catalase (CAT) on gene expression. Environ Health Prev Med 21(5):382–386. https://doi.org/10.1007/s12199-016-0540-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kalpakcioglu B, Enel K (2008) The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin Rheumatol 27(2):141–145. https://doi.org/10.1007/s10067-007-0746-3

    Article  PubMed  Google Scholar 

Download references

Funding

This work was financially supported by the Ministry of Education, Science, and Technological Development of the Republic of Serbia (Grant Number III41018).

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Biochemistry, University of Niš, Bulevar dr Zorana Djindjića 81, Niš, 18000, Serbia

    Jelena Bašić, Tatjana Jevtović-Stoimenov, Milena Despotović, Tatjana Cvetković & Dušica Pavlović

  2. Clinic of Pediatrics, Clinical Center Niš, Niš, Serbia

    Jelena Vojinović & Dragana Lazarević

  3. Faculty of Medicine, University of Niš, Niš, Serbia

    Jelena Vojinović & Mina Cvetković

  4. Institute of Rheumatology, Belgrade, Serbia

    Gordana Sušić

  5. Clinic of Neurology, Clinical Center Niš, Niš, Serbia

    Vuk Milošević

Authors
  1. Jelena Bašić
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jelena Vojinović
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatjana Jevtović-Stoimenov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Milena Despotović
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tatjana Cvetković
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dragana Lazarević
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gordana Sušić
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vuk Milošević
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mina Cvetković
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dušica Pavlović
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JB, JV, TJS and DP designed the study. JB and JV collected and interpreted data and wrote the initial draft of the manuscript. TJS, MD, TC, DL, GS, VM, MC and DP contributed to the data collection and interpretation and revised the manuscript critically. All authors approved the final version to be submitted for publication and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Jelena Bašić.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study. All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLSX 9 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bašić, J., Vojinović, J., Jevtović-Stoimenov, T. et al. The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis. Rheumatol Int 39, 551–559 (2019). https://doi.org/10.1007/s00296-019-04246-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-019-04246-3

Keywords

Search

Navigation